 manag non-smal cell lung cancer etoposid phase-specif schedule-depend deriv podophyllotoxin dna-topoisomeras II earli preclin work sharp activ mous leukemia possibl synergi cisplatin singl agent limit benefit non-smal cell lung cancer nsclc respons rate combin cisplatin mainstay chemotherapeut effort primari therapi conjunct radiat respons rate advanc diseas averag patient stage iiia iiib diseas recent work issu true synergi etoposid cisplatin nsclc reassess rel role etoposid cisplatin combin unclear sever studi pharmacokinet data suggest multipl daili fraction etoposid superior prolong infus sever futur trial current major role etoposid cisplatin multimod therapi combin radiat and/or surgeri sever agent etoposid etoposid cisplatin mitomycin vindesin doxorubicin cyclophosphamid ifosfamid carboplatin unclear addit respons surviv advantag